Ivacaftor — Discount Pricing

Other medications in Respiratory & Allergies

• Levalbuterol
• Levocetirizine
• Lumacaftor-Ivacaftor
• Mepolizumab
• Methylprednisolone IV
• Mometasone
• Mometasone Nasal
• Montelukast Sodium

About Ivacaftor

What Is Ivacaftor and What Does It Treat?

Ivacaftor is a medication used to treat cystic fibrosis (CF), a progressive, genetic disease that causes persistent lung infections and limits the ability to breathe over time. Unlike traditional CF treatments that manage symptoms, ivacaftor is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator. This means it targets the underlying cause of CF in patients with specific *CFTR* gene mutations.

It's important to note that ivacaftor is not for all CF patients. Its use is specific to individuals who have one or more copies of certain mutations in the *CFTR* gene, such as G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R, or R117H. Your doctor will perform genetic testing to determine if ivacaftor is the right treatment for you.

How Does Ivacaftor Work?

In CF, a defective or missing CFTR protein leads to the production of thick, sticky mucus that clogs the lungs, pancreas, and other organs. Ivacaftor works by binding to the defective CFTR protein at the cell surface and improving its function. It acts as a "potentiator," essentially opening the chloride channel in the CFTR protein more effectively and for longer periods.

By improving the function of the CFTR protein, ivacaftor helps to increase the flow of chloride and water across cell membranes. This, in turn, helps to thin the thick mucus, making it easier to clear from the airways and improving the function of affected organs. Patients on ivacaftor often experience improved lung function, reduced pulmonary exacerbations, better weight gain, and an overall improvement in their quality of life.

Typical Costs of Ivacaftor

Ivacaftor is a specialty medication, and like many innovative treatments for rare diseases, it comes with a significant price tag. Without insurance or discounts, the annual cost of ivacaftor can be exceedingly high, often ranging into hundreds of thousands of dollars. These costs reflect the extensive research, development, and clinical trials required to bring such a targeted and effective therapy to market.

How TheDrugClub Helps Members Save

Understanding the financial burden of medications like ivacaftor, TheDrugClub offers several avenues for members to access more affordable pricing. While we cannot guarantee that ivacaftor will be free or fully covered, we empower our members with options:

1. Active-Formulary Benefits: For members with prescription

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Ivacaftor is approved for (FDA label)

KALYDECO is indicated for the treatment of cystic fibrosis (CF) in patients aged 1 month and older who have at least one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data [see Clinical Pharmacology (12.1) and Clinical Studies (14) ] . If the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of a CFTR mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions for use.

Source: Read the full FDA label on DailyMed. Label effective date: March 23, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Ivacaftor (FDA label)

Tablets: 150 mg, light blue, film-coated, oblong-shaped tablets, with the characters "V 150" on one side and plain on the other. Oral granules: 5.8 mg, 13.4 mg, 25 mg, 50 mg, or 75 mg, white to off-white granules, in unit-dose packets. Tablets: 150 mg. ( 3 ) Oral granules: Unit-dose packets of 5.8 mg, 13.4 mg, 25 mg, 50 mg, and 75 mg. ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 0ab0c9f8-3eee-4e0f-9f3f-c1e16aaffe25. SPL document ID: 13eb3fc2-0dac-4ada-96a8-a2e0cea711b7. Label effective date: March 23, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Ivacaftor (FDA label)

The following adverse reactions are discussed in greater detail in other sections of the labeling: Transaminase Elevations [ see Warnings and Precautions (5.1) ] Hypersensitivity Reactions, Including Anaphylaxis [see Warnings and Precautions (5.2) ] Intracranial Hypertension [see Warnings and Precautions (5.3) ] Neuropsychiatric Events, Including Suicidal Thoughts and Behaviors [see Warnings and Precautions (5.4) ] Cataracts [see Warnings and Precautions (5.6) ] The most common adverse drug reactions to KALYDECO (≥8% of patients with CF who have a G551D mutation in the CFTR gene) were headache, oropharyngeal pain, upper respiratory tract infection, nasal congestion, abdominal pain, nasopharyngitis, diarrhea, rash, nausea, and dizziness. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Vertex Pharmaceuticals Incorporated at 1-877-634-8789 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Source: FDA prescribing information (DailyMed). Set ID: 0ab0c9f8-3eee-4e0f-9f3f-c1e16aaffe25. SPL document ID: 13eb3fc2-0dac-4ada-96a8-a2e0cea711b7. Label effective date: March 23, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.